The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Cyclooxygenase-2 in Synaptic Signaling
Open accessAbstract
Cyclooxygenase-2 (COX-2), a rate-limiting enzyme converting arachidonic acid to prostaglandins and a key player in neuroinflammation, has been implicated in the pathogenesis of neurodegenerative diseases such as multiple sclerosis, Parkinson's and Alzheimer's diseases, and in traumatic brain injury- and ischemia-induced neuronal damage, and epileptogenesis. Accumulated information suggests that the contribution of COX-2 to neuropathology is associated with its involvement in synaptic modification. Inhibition or elevation of COX-2 has been shown to suppress or enhance excitatory glutamatergic neurotransmission and long-term potentiation (LTP). These events are mainly mediated via PGE(2), the predominant reaction product of COX-2, and the PGE(2) subtype 2 receptor (EP(2))-protein kinase A pathway. Recent evidence shows that endogenous cannabinoids are substrates for COX-2 and can be oxygenated by COX-2 to form new classes of prostaglandins (prostaglandin glycerol esters and prostaglandin ethanolamides). These COX-2 oxidative metabolites of endocannabinoids, as novel signaling mediators, modulate synaptic transmission and plasticity and cause neurodegeneration. The actions of these COX-2 metabolites are likely mediated by mitogen-activated protein kinase (MAPK) and inositol 1,4,5-trisphosphate (IP(3)) signal transduction pathways. These discoveries suggest that the contributions of COX-2 to neurotransmission and brain malfunction result not only from its conversion of arachidonic acid to classic prostaglandins but also from its oxidative metabolism of endocannabinoids to novel prostaglandins. Thus, elucidation of COX-2 in synaptic signaling may provide a mechanistic basis for designing new drugs aimed at preventing, treating or alleviating neuroinflammation-associated neurological disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COX-2 overexpression increases PGE-2 resulting in glutamatergic excitability, stimulation of corticotropin-releasing hormone, and the release of pro-inflammatory cytokines (159).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [159]
In the citing paper
“blocking COX-2 will limit the production of the active oxidative metabolites of AEA (prostaglandin-Gs) and 2-AG (prostaglandin-EAs), that are posited to exert their own effects at as yet to be determined receptors (Hu et al., 2008; Sang et al., 2006; Yang and Chen, 2008).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Yang and Chen, 2008
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
“2 previously is generated by the actions of cyclooxygenases on AA [4, 91, 93].”
BackgroundRegulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“COX-2 overexpression increases PGE-2 resulting in glutamatergic excitability, stimulation of corticotropin-releasing hormone, and the release of pro-inflammatory cytokines (159).”
BackgroundChen, C., Liao, J., Xia, Y., Liu, X., Jones, R., Haran, J., McCormick, B., Sampson, T. R., Alam, A., & Ye, K. (2022) · Gut · doi:10.1136/gutjnl-2021-326269 · Cited by 491
Self-citationKubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.026 · Cited by 443
Metadata
- Authors
- Yang, H., & Chen, C.
- Affiliations
- Louisiana State University Health Sciences Center New Orleans (US)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 14
- Issue
- 14
- Pages
- 1443-1451
- ISSN
- 1381-6128 (ISSN-L)
- PMC
- PMC2561288
- OpenAlex
- W2083843309
- Cited by
- 195
- References
- 138
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 5 · 2014: 10 · 2013: 10 · 2012: 9
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS054886)
- National Center for Research Resources (P20RR-16816, P20RR016816)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- cyclooxygenase-2, synaptic signaling, prostaglandin E2, endocannabinoids, neuroinflammation, long-term potentiation, glutamatergic neurotransmission, synaptic plasticity, neurodegenerative diseases, traumatic brain injury, ischemic neuronal injury, epileptogenesis, MAPK signaling, IP3 signaling, COX-2 inhibitors
- MeSH terms
- Animals, Humans, Synaptic Transmission, Neuronal Plasticity, Oxidation-Reduction, Synapses, Drug Design, Dinoprostone, Signal Transduction, Receptors, Prostaglandin E, Cyclooxygenase 2, Receptors, Prostaglandin E, EP2 Subtype, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenase-2 in Synaptic Signaling. https://app.cochat.ai/papers/10.2174/138161208784480144
- The paper
- Yang, H., & Chen, C. (2008). Cyclooxygenase-2 in Synaptic Signaling. Current Pharmaceutical Design. https://doi.org/10.2174/138161208784480144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.